KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Equity (2016 - 2025)

Historic Return on Equity for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to 0.18%.

  • Alnylam Pharmaceuticals' Return on Equity rose 228700.0% to 0.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18%, marking a year-over-year increase of 228700.0%. This contributed to the annual value of 3.62% for FY2024, which is 13000.0% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Return on Equity of 0.18% as of Q3 2025, which was up 228700.0% from 1.74% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Return on Equity high stood at 10.02% for Q4 2022, and its period low was 22.69% during Q3 2024.
  • Moreover, its 5-year median value for Return on Equity was 1.0% (2021), whereas its average is 2.08%.
  • Its Return on Equity has fluctuated over the past 5 years, first surged by 235900bps in 2023, then crashed by -244700bps in 2024.
  • Alnylam Pharmaceuticals' Return on Equity (Quarter) stood at 1.27% in 2021, then skyrocketed by 889bps to 10.02% in 2022, then crashed by -77bps to 2.28% in 2023, then tumbled by -346bps to 5.59% in 2024, then soared by 103bps to 0.18% in 2025.
  • Its Return on Equity was 0.18% in Q3 2025, compared to 1.74% in Q2 2025 and 2.96% in Q1 2025.